1. TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia
   Susana Martin‐Rodriguez et al, 2015, European Journal of Clinical Investigation CrossRef
2. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation
   Eun Ji Lee et al, 2015, The FASEB Journal CrossRef
3. MicroRNA-106 attenuates hyperglycemia-induced vascular endothelial cell dysfunction by targeting HMGB1
   Rui Liu et al, 2018, Gene CrossRef
4. Role of high mobility group box 1 and its signaling pathways in renal diseases
   Tian-Biao Zhou, 2014, Journal of Receptors and Signal Transduction CrossRef
5. High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
   Eyaldeva C. Vijayakumar et al, 2019, Current Drug Targets CrossRef
6. HMGB1 in health and disease
   Rui Kang et al, 2014, Molecular Aspects of Medicine CrossRef
7. Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes
   Gina Manda et al, 2015, Mediators of Inflammation CrossRef
8. HMGB1, TGF‑β and NF‑κB are associated with chronic allograft nephropathy
   Shi‑Qi Zhao et al, 2017, Experimental and Therapeutic Medicine CrossRef
9. Soluble Receptor for Advanced Glycation End Product Ameliorates Chronic Intermittent Hypoxia Induced Renal Injury, Inflammation, and Apoptosis via P38/JNK Signaling Pathways
   Xu Wu et al, 2016, Oxidative Medicine and Cellular Longevity CrossRef
10. Allopurinol preconditioning attenuates renal ischemia/reperfusion injury by inhibiting HMGB1 expression in a rat model
    Jiang-qiao Zhou et al, 2016, Acta Cirurgica Brasileira CrossRef
11. High Mobility Group Box 1 Promotes Aortic Calcification in Chronic Kidney Disease via the Wnt/β-Catenin Pathway
    Xiucai Jin et al, 2018, Frontiers in Physiology CrossRef
12. Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity
    Anna A. Zmijewska et al, 2021, American Journal of Transplantation CrossRef
13. High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review
    Seidu A. Richard et al, 2018, AIMS Molecular Science CrossRef
14. The role of the high-mobility group box1 protein–Toll like receptor pathway in diabetic vascular disease
    Roma Pahwa et al, 2016, Journal of Diabetes and its Complications CrossRef
15. Complement-mediated Damage to the Glycocalyx Plays a Role in Renal Ischemia-reperfusion Injury in Mice
    Anjan K. Bongoni et al, 2019, Transplantation Direct CrossRef
16. Hypoxic human proximal tubular epithelial cells undergo ferroptosis and elicit an NLRP3 inflammasome response in CD1c+ dendritic cells
    Kurt T. K. Giuliani et al, 2022, Cell Death & Disease CrossRef
17. Fibrosis
    Jeremy S. Duffield, 2016, Kidney Development, Disease, Repair and Regeneration CrossRef
18. Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants
    Onur Sazpinar et al, 2022, Frontiers in Medicine CrossRef
19. Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases
    Eun Ji Lee et al, 2013, Genomics & Informatics CrossRef
20. The NLRP3/ASC inflammasome promotes T-cell-dependent immune complex glomerulonephritis by canonical and noncanonical mechanisms
    Kirstin Andersen et al, 2014, Kidney International CrossRef
21. Serum level of high mobility group box protein-1 and prognosis of patients with end-stage renal disease on hemodialysis and peritoneal dialysis
    Linyan Chen et al, 2021, Medicine CrossRef
22. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway
    Di Yao et al, 2018, Molecular Medicine Reports CrossRef
23. High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury
    Shuo Wang et al, 2020, Journal of Translational Medicine CrossRef